30 closest matches · ranked by relevance
Improve Endothelial Function and Decrease Vascular Stenosis
Primary: Change in Baseline and 2 Week FMD/VP Measurements Between Sildenafil Group and Placebo Group — 10.8; 8.6 Change in FMD%
End-Stage Renal Disease (ESRD)
Primary: Number of Participants With Adverse Events (AEs) — 8 participants
Chronic Kidney Disease
Primary: Patient Activation Measure (PAM) -13 Item Questionnaire — 9.1; -1.4 points — p=0.01
Anemia · End Stage Renal Disease (ESRD)
Primary: Change From Baseline (BL) to the Average Hemoglobin (Hb) in Weeks 28-36 Without Rescue Therapy [EU (EMA)] — 0.428; 0.193 g/dL — p=<0.001
End Stage Renal Disease on Hemodialysis (Diagnosis)
Primary: Percentage of Subjects Reporting Clinically Significant Adverse Events - Medically-attended Adverse Events, Serious Adverse Events, and Immune-mediated Adverse Events of…
Chronic Kidney Disease
Primary: Maximal Oxygen Uptake — 14.5; 15.1 ml/kg/min
Hyperphosphatemia · End-stage Renal Disease · Renal Failure Chronic Requiring Hemodialysis
Primary: The Primary Outcome of This Trial Will be the Change in Serum Phosphorus From Baseline to End of Treatment After a Four Week Treatment Period. — -1.53 mg/dL
End Stage Renal Disease
Primary: Number of Participants With Mean PTH ≤ 300 pg/mL — 262; 41 Participants — p=<0.001
End Stage Renal Disease · Anemia
Primary: Number of Participants With Week 7 Hb ≥ Baseline Hb - 0.5 g/dL, Among Normoresponder Participants Treated for 6 Weeks Only — 4; 8; 7; 4 Participants — p=1.0000
Chronic Kidney Disease
Primary: Mortality — 0; 0 percentage of mortality
End Stage Kidney Disease
Primary: Percent of Time in Range (TIR) Between 70-180 mg/dL — 80.4; 94.0 percentage of time
Diabetes · Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2
Primary: Mean Absolute Relative Difference Between CGM Value and Capillary Blood Glucose (Self-monitoring Blood Glucose [SMBG]) — 13.8 percent difference
ESRD
Primary: Change in Leucine Disposal Rate (LDR) — -0.011; 0.005; 0.001 mg/kg/min — p=0.37
End-stage Renal Disease (ESRD)
Primary: Number of Participants With Major Bleeding (MB) and Clinically Relevant Non-Major Bleeding (CRNMB) — 3; 2; 3; 3 Participants
Kidney Failure, Chronic
Primary: Change From Baseline in PRA — -0.706; -2.176; -1.688; -2.353 percentage of population — p=0.324
End Stage Renal Disease · Kidney Failure · Renal Failure
Primary: Safety Parameters — 142; 35; 75; 0 participants
Antithrombotic
Primary: The Number of Adverse Events (AEs), Serious AEs (SAEs), AEs Leading to Discontinuation and Death — 4; 4; 3; 2 Participants
Renal Insufficiency, Chronic
Primary: Number of Participants With Sufficient Patency for Clinical Access — 20 Participants
Hyperphosphatemia
Primary: Change in Serum Phosphorus Levels During Placebo Controlled Randomized Withdrawal Period in the Responder Population — 0.43; 1.80 mg/dL — p=<0.0001
End Stage Renal Disease
Primary: Reduction Ratio of Lambda Immunoglobulin FLC at Week 24 — 32.156; 17.514 percentage ratio
Chronic Kidney Disease
Primary: Preference for Shared Decision Making — 22; 19; 35; 44 participants
Hyperphosphatemia · End-stage Renal Disease
Primary: The Difference in Serum Phosphorus Between Baseline (Day 0) and End of Treatment (Day 28) — 5.9; 5.4 mg/dL
Anaemia
Primary: Area Under the Concentration-time Curve (AUC) Over the Dosing Interval (AUC[0-tau]) of GSK1278863 and Its Metabolites — 184.9863; 138.6511; 162.9366; 131.2826 Hour into…
Chronic Kidney Disease · End Stage Renal Disease
Primary: Change in IGF-1 After 30 Days of Intervention Compared to Baseline Level. — 92.7; 6.7 ng/ml — p=<0.001
End-stage Renal Disease · Cardiovascular Disease
Primary: Pharmacokinetic Parameters of Ranolazine — 0.65 mcg/mL
Chronic Renal Anemia
Primary: Time to Composite of All-Cause Mortality and Non-Fatal Cardiovascular Events (Myocardial Infarction, Stroke) Defined as Time Between First Dose of Study Medication and…
Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis
Primary: Cumulative Excretion of Radioactivity — 35.29; 24.26; 0.75; 2.40 Percentage of administered dose
Chronic Kidney Diseases · Hypertension · Diabetes
Primary: Number of Participants With CKD Diagnosis — 417; 389 Participants — p=.21
Chronic Kidney Diseases
Primary: The Patient Activation Measure (PAM) — 60.8; 61.5; 1.73; 3.44 score on a scale
Kidney Disease, End-Stage
Primary: Symptoms - Trajectory of Change — 77.2; 76.2 score on a scale — p=0.30